Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation [Seeking Alpha]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Seeking Alpha
Follow Play 10min Summary Bezuclastinib showed promising efficacy in AdvSM but had safety concerns at higher doses, leading to mixed analyst opinions and a cautious outlook. Positive phase 2 data in nonAdvSM and GIST trials indicate potential, yet bezuclastinib struggles to differentiate from competitors like avapritinib. Financially, Cogent Biosciences has a market cap of $1.19bn and a cash runway of 5-6 quarters, supporting ongoing trials. Despite recent gains, bezuclastinib's uncertain competitive edge and upcoming catalysts make me hesitant to invest now. I'll stay on the sidelines. koto_feja In my last report on Cogent Biosciences ( NASDAQ: COGT ), that was from August 2023, I said that their molecule was increasingly differentiating itself as a novel KIT inhibitor. The company had emerging positive clinical data for bezuclastinib in advanced systemic mastocytosis (AdvSM) from About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
- Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.MarketBeat
- Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsGlobeNewswire
- Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) MeetingGlobeNewswire
COGT
Earnings
- 11/12/24 - Miss
COGT
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- COGT's page on the SEC website